Current Report Filing (8-k)
April 13 2020 - 8:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): April 8, 2020
Commission
File No. 000-16929
Soligenix,
Inc.
(Exact
name of small business issuer as specified in its charter)
DELAWARE
|
|
41-1505029
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(I.R.S.
Employer
Identification Number)
|
|
|
|
29
Emmons Drive,
Suite B-10
Princeton, NJ
|
|
08540
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(609)
538-8200
|
(Issuer’s
telephone number, including area code)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.001 per share
|
|
SNGX
|
|
The
Nasdaq Capital Market
|
Common
Stock Purchase Warrants
|
|
SNGXW
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Items.
In
response to the coronavirus (COVID-19) pandemic, the U.S. Small Business Administration (the “SBA”) is making available
low-interest rate loans to qualified small businesses, including under its Paycheck Protection Program (the “PPP”).
In
order to supplement its cash balance, Soligenix, Inc. (the “Company”) has submitted an application for non-dilutive
funding under the PPP as part of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)
administered by the SBA. Section 1106 of the CARES Act provides for forgiveness of up to the full principal amount of qualifying
loans guaranteed under the PPP. The PPP and loan forgiveness are intended to provide economic relief to small businesses, such
as the Company, that are adversely impacted under the Coronavirus Disease 2019 (COVID-19) Emergency Declaration (COVID-19 Emergency
Declaration) issued by President Trump on March 13, 2020.
No
assurance can be given that the Company will qualify for and/or receive any loan proceeds from the PPP.
Cautionary
Statement regarding Forward-Looking Statements
This
report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties and reflect the Company’s judgment as of the date of this report. Such forward-looking statements
involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. The inclusion
of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved.
Actual results may differ from those set forth in this report due to the uncertainties related to the PPP and the application
and approval process associated therewith, as well as risks and uncertainties inherent in the Company’s business, including
those described in the Company’s periodic filings with the U.S. Securities and Exchange Commission. These forward-looking
statements are made only as the date hereof, and, except as required by law, the Company undertakes no obligation to update or
revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking
statements are qualified in their entirety by this cautionary statement.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Soligenix,
Inc.
|
April
13, 2020
|
By:
|
/s/
Christopher J. Schaber
|
|
|
Christopher
J. Schaber, Ph.D.
President
and Chief Executive Officer
(Principal
Executive Officer)
|
2
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Apr 2023 to Apr 2024